Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Macrogenics (MGNX)

Macrogenics (MGNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 514,059
  • Shares Outstanding, K 48,958
  • Annual Sales, $ 60,120 K
  • Annual Income, $ -171,450 K
  • 60-Month Beta 2.32
  • Price/Sales 8.90
  • Price/Cash Flow N/A
  • Price/Book 1.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.71
  • Number of Estimates 6
  • High Estimate 0.22
  • Low Estimate -1.42
  • Prior Year -1.06
  • Growth Rate Est. (year over year) +33.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.17 +15.59%
on 01/31/20
12.51 -15.27%
on 01/22/20
-0.66 (-5.86%)
since 01/17/20
3-Month
7.43 +42.76%
on 11/21/19
12.51 -15.27%
on 01/22/20
+1.93 (+22.26%)
since 11/19/19
52-Week
7.43 +42.76%
on 11/21/19
22.57 -53.03%
on 02/20/19
-11.55 (-52.14%)
since 02/19/19

Most Recent Stories

More News
MacroGenics Announces Date of Fourth Quarter and Full Year 2019 Financial Results Conference Call

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

MGNX : 10.60 (+0.95%)
MacroGenics to Participate in Upcoming Investor Conferences

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

MGNX : 10.60 (+0.95%)
% Return Seen to Date on SmarTrend Macrogenics Inc Call (MGNX)

SmarTrend identified a Downtrend for Macrogenics Inc (NASDAQ:MGNX) on December 19th, 2019 at $10.87. In approximately 1 month, Macrogenics Inc has returned 14.86% as of today's recent price of $9.25.

MGNX : 10.60 (+0.95%)
MacroGenics to Present at the J.P. Morgan Healthcare Conference

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

JPM : 136.35 (+0.52%)
MGNX : 10.60 (+0.95%)
Look for Shares of Macrogenics Inc to Potentially Pullback after Yesterday's 1.63% Rise

Macrogenics Inc (NASDAQ:MGNX) traded in a range yesterday that spanned from a low of $11.19 to a high of $11.64. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of...

MGNX : 10.60 (+0.95%)
MacroGenics Outlines Corporate Priorities for 2020

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

MGNX : 10.60 (+0.95%)
MacroGenics Announces Submission of Margetuximab Biologics License Application to U.S. FDA

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced...

MGNX : 10.60 (+0.95%)
Shares of MGNX Down 49.1% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Macrogenics Inc (NASDAQ:MGNX) on March 6th, 2019 at $19.60. In approximately 10 months, Macrogenics Inc has returned 49.11% as of today's recent price of $9.98.

MGNX : 10.60 (+0.95%)
Macrogenics Inc Rises 1.16% on Heavy Volume: Watch For Potential Pullback

Macrogenics Inc (NASDAQ:MGNX) traded in a range yesterday that spanned from a low of $10.15 to a high of $10.67. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high of...

MGNX : 10.60 (+0.95%)
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END

MGNX : 10.60 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade MGNX with:

Business Summary

MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics...

See More

Key Turning Points

2nd Resistance Point 10.81
1st Resistance Point 10.65
Last Price 10.60
1st Support Level 10.22
2nd Support Level 9.95

See More

52-Week High 22.57
Fibonacci 61.8% 16.78
Fibonacci 50% 15.00
Fibonacci 38.2% 13.21
Last Price 10.60
52-Week Low 7.43

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar